Standardized pneumonia response alone does not specify the treatment estimand

By
Meiting Li
Mengyan Sun
Wenzhen Zhuo
Xiaoyang Gong
November 2, 2026

Critical Care

At a Glance

Category	Detail
Condition	Hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP)
Key Mechanisms	The article discusses how death before pneumonia-response assessment and other events that preclude assessment affect the treatment estimand and interpretation of randomized comparisons.
Target Population	Ventilated patients with HAP/VAP and participants in interventional studies evaluating pneumonia treatment response
Care Setting	Hospital and intensive care settings; randomized-trial design and analysis of HAP/VAP treatment outcomes

Key Highlights

A standardized pneumonia-response measure does not, by itself, define the treatment effect a randomized trial estimates.
Among 1,603 pneumonia episodes, 302 had an indeterminate overall treatment outcome; death accounted for 240, and classifying death as failure increased the failure proportion from 22.2% to 34.3%.
Comparisons limited to patients alive and classifiable at day 10 may compare treatment-specific survivor groups and may not retain the randomized causal contrast when treatment affects survival.
The authors recommend prespecifying the target population, treatment conditions, response variable, strategy for death and other precluding events, and treatment-effect summary measure.
Prognostic associations among assessable patients support discrimination by the response classification but address a different question from the causal interpretation of survivor-conditioned treatment comparisons.

Guideline-Based Recommendations

Diagnosis

The article concerns evaluation of treatment response in ventilated patients with HAP/VAP; it does not provide diagnostic criteria for pneumonia.

Management

For interventional studies, specify the estimand alongside the response criteria rather than requiring one universal approach to death.
Consider defining a global outcome that includes death, such as a composite or a Desirability of Outcome Ranking (DOOR) framework incorporating response, complications, adverse events, and mortality.
If the target question concerns people who would survive under either treatment, a principal-stratum estimand such as the survivor average causal effect may be considered; randomization alone does not identify membership in that stratum without additional assumptions.

Monitoring & Follow-up

Prospective interventional studies should evaluate reproducibility of the response criteria and the effects of prespecified approaches to death and other events that preclude outcome assessment.
Prespecify the target population, treatment conditions, response variable, intercurrent-event strategy, and treatment-effect summary measure.

Risks

Restricting analysis to patients alive and classifiable at day 10 can produce treatment-specific survivor groups that are not comparable if treatment affects early survival.
Classifying death differently can represent distinct scientific questions and treatment effects, not merely alternative analyses of the same effect.
Validation analyses in selected post-baseline populations support prognostic discrimination among observable patients but do not establish that survivor-conditioned comparisons preserve the randomized causal contrast.

Patient & Prescribing Data

The cited cohort included 1,603 HAP/VAP episodes; 302 had an indeterminate overall treatment outcome, including 240 deaths. The article does not provide prescribing or dosing data.

Classifying death as treatment failure increased the reported failure proportion from 22.2% to 34.3%. The article addresses trial estimands and outcome interpretation, not treatment selection or prescribing.

Clinical Best Practices

Define the treatment estimand explicitly when applying pneumonia-response criteria in interventional research.
Prespecify how death and other events that prevent outcome assessment will be handled.
Distinguish descriptive analyses among observed survivors from analyses intended to estimate a randomized causal treatment effect.
Interpret prognostic validation in assessable patients separately from causal comparisons between randomized treatment groups.